The Leukocyte Surface Antigen CD47 Antibody Market is segmented by product type, with monoclonal antibodies holding the largest share. Monoclonal antibodies (mAbs) that block CD47 are the most advanced class of CD47-targeting agents. These antibodies bind to CD47 and prevent it from interacting with its receptor, SIRPα, on macrophages, thereby restoring phagocytosis. Magrolimab is the most advanced CD47 mAb, with several other candidates in clinical development.

While monoclonal antibodies lead, bispecific antibodies are the fastest-growing segment. Bispecific antibodies are engineered to bind to two different targets simultaneously. CD47 bispecific antibodies are designed to bind to both CD47 on cancer cells and a tumor-associated antigen (TAA) on the same cell. This dual targeting approach is intended to improve tumor specificity, reducing off-target toxicity, and enhance therapeutic efficacy. Several CD47 bispecific antibodies are in early-stage clinical development.

Combination therapies represent another significant growth area. CD47 antibodies are being evaluated in combination with a variety of other agents, including chemotherapy, targeted therapies, and other immunotherapies (such as PD-1/PD-L1 inhibitors). The rationale is that combination therapy may overcome resistance and produce synergistic effects. For example, combining a CD47 antibody with a PD-1 inhibitor could activate both the innate and adaptive immune systems, leading to a more robust anti-tumor response. The combination of magrolimab with azacitidine has shown promising activity in MDS and AML.

Other product types include SIRPα-Fc fusion proteins, which act as decoy receptors to block the CD47-SIRPα interaction.

The growth of the bispecific and combination therapy segments is driven by the need to improve the therapeutic index of CD47-targeting agents. The first-generation CD47 mAbs were associated with significant on-target, off-tumor toxicity, particularly anemia. Next-generation approaches aim to enhance tumor specificity and reduce systemic exposure, improving safety and potentially efficacy.